Skip to search formSkip to main contentSkip to account menu

EORTC GIMEMA AML-10 protocol

National Institutes of Health

Related topics

Related topics

6 relations

Broader (6)

Antineoplastic Combined Chemotherapy ProtocolsCytarabineDaunorubicinEtoposide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01…
Introduction : Cytogenetic abnormalities by fluorescence in situ hybridization (FISH) are clinically relevant prognostic factors… 
2014
2014
Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study
Background: The phase 3 GIMEMA-MMY-3006 study comparing bortezomib-thalidomide-dexamethasone (VTD) vs. thalidomide-dexamethasone… 
2012
2012
Chromosome 1 abnormalities predict poor overall survival in elderly newly diagnosed multiple myeloma patients enrolled in the gimema-MM-03-05 randomized controlled trial
2004
2004
Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post…
Twenty-six adult patients (pts) aged between 22 and 60 years (median age: 46) with BCR-ABL+ acute lymphoblastic leukemia (ALL… 
1990
1990
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.
We report 2 new cases of thrombosis occurring in a cohort of 21 consecutive patients with acute lymphocytic leukemia treated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)